scholarly journals “RINOVIN” Injection Therapis as a Non-specific Hyposensitization of Nasal Allergy

1974 ◽  
Vol 67 (1) ◽  
pp. 81-87
Author(s):  
Tomonori TAKASAKA ◽  
Noriko YAOITA ◽  
Yonosuke UENO ◽  
Yoshiki SATO ◽  
Akira ONODERA
Keyword(s):  
Nasal Allergy ◽  
Specific Hyposensitization

scholarly journals Treatment of perennial nasal allergy by N-5' and specific hyposensitization.

1985 ◽  
Vol 78 (1) ◽  
pp. 145-153
Author(s):  
Motoo Takaoka ◽  
Takeo Suzuki ◽  
Hiromi Takeuchi ◽  
Yukisato Kitamura ◽  
Hisaaki Ikoma
Keyword(s):  
Nasal Allergy ◽  
Specific Hyposensitization

scholarly journals Surgical treatment of the nasal allergy

1977 ◽  
Vol 70 (7) ◽  
pp. 677-678
Author(s):  
Ryo Takahashi
Keyword(s):  
Surgical Treatment ◽  
Nasal Allergy

scholarly journals Recent advances in allergic rhinitis

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1333 ◽  
Author(s):  
Flavia C. L. Hoyte ◽  
Harold S. Nelson
Keyword(s):  
Allergic Rhinitis ◽  
Work Productivity ◽  
Allergen Challenge ◽  
Economic Cost ◽  
Symptomatic Treatment ◽  
The United States ◽  
Specific Ige ◽  
Subcutaneous Immunotherapy ◽  
Nasal Allergy

Allergic rhinitis affects 20 to 30% of adults in both the United States and Europe and perhaps a somewhat higher percentage of children. In addition to nasal and ocular symptoms directly related to the allergic process, interference of these symptoms with sleep leads to daytime sleepiness and impaired quality of life. Patients miss work because of symptoms but an even greater problem is interference with work productivity, or presenteeism, which has been reported to be the biggest contributor to the total economic cost of allergic rhinitis. There has been increasing awareness that many patients with either seasonal or perennial symptoms but negative skin and in vitro tests for allergen sensitivity have local nasal allergy, diagnosable by the presence of allergen-specific IgE in their nasal secretions or a positive nasal allergen challenge or both. The pharmaceutical management of allergic rhinitis rests on symptomatic treatment with antihistamines that perhaps are more effectively administered intranasally than orally and intranasal corticosteroids. Allergen immunotherapy is very effective, even for local allergic rhinitis, and the shortcomings of subcutaneous immunotherapy of inconvenience and safety are reduced by the introduction of sublingual immunotherapy (SLIT). Use of the latter is currently somewhat limited by the lack of appropriate dosing information for SLIT liquids and the limited number of allergens for which SLIT tablets are available.

scholarly journals Protection of Plasminogen Activator Inhibitor-1-Deficient Mice from Nasal Allergy

2005 ◽  
Vol 174 (12) ◽  
pp. 8135-8143 ◽  
Author(s):  
Takayuki Sejima ◽  
Seiji Madoiwa ◽  
Jun Mimuro ◽  
Teruko Sugo ◽  
Kiyotaka Okada ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Nasal Allergy ◽  
Plasminogen Activator Inhibitor 1 ◽  
Deficient Mice ◽  
Activator Inhibitor

scholarly journals Clinical evaluation of AA-673 tablets in patients with refrectory perannial nasal allergy.

1989 ◽  
Vol 82 (10) ◽  
pp. 1485-1496
Author(s):  
Toru Matsunaga ◽  
Satoshi Ogino ◽  
Tadao Enomoto
Keyword(s):  
Clinical Evaluation ◽  
Nasal Allergy
Sign in / Sign up

Export Citation Format

Share Document